ArticleCPT: pharmacometrics & systems pharmacology2019
A Holistic and Integrative Approach for Advancing Model-Informed Drug Development.
Article in CPT: pharmacometrics & systems pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 Infection.Clinical pharmacology and therapeutics · 2021Trial
- Quantitative Systems Pharmacology (QSP): Bridging Biology and Mechanism with Clinical Drug Development Decisions.Journal of clinical pharmacology · 2026Review
- Innovative Clinical Pharmacology, Modeling, and Simulation Strategies for Accelerating Rare Disease Drug Development.Journal of clinical pharmacology · 2026Review
- Advancing drug development with "Fit-for-Purpose" modeling informed approaches.Journal of pharmacokinetics and pharmacodynamics · 2025Review
- FDA and EMA Oversight of Disruptive Science on Application of Finite Absorption Time (F.A.T.) Concept in Oral Drug Absorption: Time for Scientific and Regulatory Changes.Pharmaceutics · 2024Article
- Review
- Model-informed drug development for immuno-oncology agonistic anti-GITR antibody GWN323: Dose selection based on MABEL and biologically active dose.Clinical and translational science · 2022Article
- Quantitative system pharmacology as a legitimate approach to examine extrapolation strategies used to support pediatric drug development.CPT: pharmacometrics & systems pharmacology · 2022Review
- IVIVE: Facilitating the Use ofToxics · 2022Review
- Dose-finding studies in drug development for rare genetic diseases.Orphanet journal of rare diseases · 2022Article
- Nanomedicine Ex Machina: Between Model-Informed Development and Artificial Intelligence.Frontiers in digital health · 2022Review
- Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility.CPT: pharmacometrics & systems pharmacology · 2021Article
- Clinical Pharmacology Regulatory Sciences in Drug Development and Precision Medicine: Current Status and Emerging Trends.The AAPS journal · 2021Article
- A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes.Pharmaceutics · 2021Article
- Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.Clinical pharmacology and therapeutics · 2021Review
- Opportunities and challenges for applying model-informed drug development approaches to gene therapies.CPT: pharmacometrics & systems pharmacology · 2021Review
- Time to Expect More From Pharmacometrics.Clinical pharmacology and therapeutics · 2020Article
- MID3: Mission Impossible or Model-Informed Drug Discovery and Development? Point-Counterpoint Discussions on Key Challenges.Clinical pharmacology and therapeutics · 2020Article
- Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.Diabetes, obesity & metabolism · 2020Article
- Artificial Intelligence and Machine Learning Applied at the Point of Care.Frontiers in pharmacology · 2020Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.